Fibronectin (FN) was shown to be present on the surface of several mesenchymal cells, such as fibroblasts and smooth muscle cells, as well as in the intercellular matrix synthesized by those cells (Hynes, 1981; Yamada, 1981) . It was shown by Hynes (1973) that most malignant transformed cells lose the capacity to retain F N on their membrane.
A similar loss of cell membrane-bound F N was shown to occur in a variety of solid human tumours (Labat-Robert et al., 1980, 198 la) accompanied by a fragmentation followed by a disappearance of F N in glandular basement membranes, but with an increase in the intensity of FNimmunofluorescence in the tumour matrix (Labat-Robert e f al., 1981~).
Although there are structural differences between plasma and tissue F N and separate genes may well be coding for them (Yamada, 1983 ) it appeared to be of interest to study a possible relationship between these two forms of F N in cancer patients. Recent results (R. Hynes, personal communication) prove the existence of one single gene. Plasma F N was determined by laser immunonephelometry. Previous studies showed an exponential increase of plasma F N with age in a control population (Labat-Robert et al., 19816).
Abbreviation used: FN, fibronectin.
We therefore studied the age dependence of plasma F N in 126 mammary cancer patients. As shown in Fig. 1 , the cancer patients exhibited a slight increase of plasma F N with age, but this was not significant when compared with the highly significant and much stronger increase with age of plasma F N in the control population (130 persons studied). The difference in the slopes of the two correlation lines (control and cancer patients, see Fig. 1 ) is significant ( P < 0.05). The two lines intersect at about 40 years of age. This could be interpreted as a decreased rate of synthesis and/or increased rate of catabolism of plasma F N above this age in mammary cancer patients. Below this age increased or unchanged plasma F N levels may be expected. This modified age dependence of plasma F N was also found in several other forms of malignancies and especially in sarcomas (J. P. Potazman et al., unpublished work). These results confirm our previous conclusion that pathological variations of plasma F N cannot be interpreted without the use of age-matched controls. 
